5 Pages
English
Gain access to the library to view online
Learn more

Frost & Sullivan: Emerging Technologies Redefine Infectious Disease Diagnostics

Gain access to the library to view online
Learn more
5 Pages
English

Description

Frost & Sullivan: Emerging TechnologiesFrost & Sullivan: Emerging Technologies Redefine Infectious Disease Diagnostics PR Newswire LONDON, April 22, 2014 -- The largest opportunities lie in the developing regions of Asia, Africa and Latin America The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America. The urgent measures taken by governments to minimize healthcare expenditure, owing to both economic and political pressures, are driving the demand particularly for high-throughput automated diagnostic platforms and point-of-care testing devices. New analysis from Frost & Sullivan, Emerging Technologies in Infectious Diseases Diagnostics, finds that the market is characterised by the constant introduction of improved devices and technologies due to their short lifecycle. For instance, new molecular technologies for the screening of drug-resistant TB are replacing culture-based tests, which are slow, require experienced personnel, and need stringent microbiological safety precautions. "Startup companies are developing diagnostic technologies from a vast array of sources and disciplines, which is giving rise to new kinds of diagnostic devices," said Technical Insights Research Analyst Geethu Roshan Verghese.

Subjects

Informations

Published by
Published 22 April 2014
Reads 51
Language English

Exrait

Frost & Sullivan: Emerging Technologies Redefine Infectious Disease Diagnostics

PR Newswire

-- The largest opportunities lie in the developing regions of Asia, Africa and Latin America

The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America. The urgent measures taken by governments to minimize healthcare expenditure, owing to both economic and political pressures, are driving the demand particularly for high-throughput automated diagnostic platforms and point-of-care testing devices.